The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection

References

• World Gastroenterology O. World gastroenterology organisation global guideline: helicobacter pylori in developing countries. J Clin Gastroenterol. 2011;45(5):383–388.
   PubMed Web of Science ®Google Scholar
• Zabaglia LM, Ferraz MA, Pereira WN, et al. Lack of association among TNF-α gene expression, −308 polymorphism (G > A) and virulence markers of Helicobacter pylori. J Venom Anim Toxins Incl Trop Dis. 2015;21:54.
   PubMed Web of Science ®Google Scholar
• Pan K-F, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65(1):9–18.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee S-Y. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44(3):537–563.
   PubMed Web of Science ®Google Scholar
• de Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995;345(8953):817–820.
   PubMed Web of Science ®Google Scholar
• Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996;1(3):138–144.
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection–the Maastricht IV/florence consensus report. Gut. 2012;61(5):646–664.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–278.
   PubMed Web of Science ®Google Scholar
• Bell GD, Bate CM, Axon AT, et al. Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Aliment Pharmacol Ther. 1995;9(5):513–520.
   PubMed Web of Science ®Google Scholar
• Delchier JC, Elamine I, Goldfain D, et al. Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10(3):263–268.
   PubMed Web of Science ®Google Scholar
• Sapmaz F, Kalkan IH, Atasoy P, et al. A non-inferiority study: modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of helicobacter pylori. Am J Ther. 2017;24(4):e393–e398.
   PubMed Web of Science ®Google Scholar
• Goh KL, Peh SC, Parasakthi N, et al. Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol. 1994;89(10):1789–1792.
   PubMed Web of Science ®Google Scholar
• Unge P, Gad A, Gnarpe H, et al. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl. 1989;167:49–54.
   PubMedGoogle Scholar
• van der Hulst RW, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1(1):6–19.
   PubMedGoogle Scholar
• Pieramico O, Zanetti MV, Innerhofer M, et al. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. Helicobacter. 1997;2(2):92–97.
   PubMed Web of Science ®Google Scholar
• Wong BC, Xiao SD, Hu FL, et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther. 2000;14(2):217–224.
   PubMed Web of Science ®Google Scholar
• Laine L, Stein C, Neil G. Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized trial employing “optimal” dosing. Am J Gastroenterol. 1995;90(9):1407–1410.
   PubMed Web of Science ®Google Scholar
• Ince AT, Tozlu M, Baysal B, et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepato-gastroenterology. 2014;61(133):1454–1458.
   PubMedGoogle Scholar
• Schmid CH, Whiting G, Cory D, et al. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials. Am J Ther. 1999;6(1):25–36.
   PubMedGoogle Scholar
• Shirai N, Sugimoto M, Kodaira C, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol. 2007;63(8):743–749.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther. 1997;11(2):323–329.
   PubMed Web of Science ®Google Scholar
• Ellenrieder V, Boeck W, Richter C, et al. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol. 1999;34(8):750–756.
   PubMed Web of Science ®Google Scholar
• Ren L, Lu H, Li HY, et al. New dual therapy for primary treatment of Helicobacter pylori infection: a prospective randomized study in Shanghai, China. J Dig Dis. 2014;15(11):622–627.
   PubMed Web of Science ®Google Scholar
• Yu L, Luo LS, Long XH, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019; 24(4):e12596
   PubMed Web of Science ®Google Scholar
• Bayerdörffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995;108(5):1412–1417.
   PubMed Web of Science ®Google Scholar
• Kim SY, Jung SW, Kim JH, et al. Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br J Clin Pharmacol. 2012;73(1):140–143.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003;8(4):310–319.
   PubMed Web of Science ®Google Scholar
• Yang J-C, Lin C-J, Wang H-L, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905.e895.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of helicobacter pylori. Am J Gastroenterol. 2019;114(3):437–445.
   PubMed Web of Science ®Google Scholar
• Tai W-C, Liang C-M, Lee C-H, et al. Seven-day nonbismuth containing quadruple therapy could achieve a grade “A” success rate for first-line helicobacter pylori eradication. Biomed Res Int. 2015;2015:623732.
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemoth. 2019;74(6):1718–1724.
   PubMed Web of Science ®Google Scholar
• Kwack W, Lim Y, Lim C, et al. High dose ilaprazole/amoxicillin as first-line regimen for helicobacter pylori infection in Korea. Gastroenterol Res Pract. 2016;1–7. DOI:10.1155/2016/1648047
   PubMed Web of Science ®Google Scholar
• Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–533.
   PubMed Web of Science ®Google Scholar
• Shiota S, Reddy R, Alsarraj A, et al. Antibiotic resistance of helicobacter pylori among male United States Veterans. Clin Gastroenterol Hepatol. 2015;13(9):1616–1624.
   PubMed Web of Science ®Google Scholar
• Smith SM, O’Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35(1):6–13.
   PubMed Web of Science ®Google Scholar
• Kuo Y-T, Liou J-M, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):707–715.
   PubMed Web of Science ®Google Scholar
• Windham IH, Merrell DS. Analysis of fitness costs associated with metronidazole and amoxicillin resistance in Helicobacter pylori. Helicobacter. 2020;25(5):e12724.
   PubMed Web of Science ®Google Scholar
• Barbhaiya R, Thin RN, Turner P, et al. Clinical pharmacological studies of amoxycillin: effect of probenecid. Br J Vener Dis. 1979;55(3):211–213.
   PubMedGoogle Scholar
• Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258–266.
   PubMed Web of Science ®Google Scholar
• Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56–S60.
   PubMed Web of Science ®Google Scholar
• Grayson ML, Eliopoulos GM, Ferraro MJ, et al. Effect of varying Ph on the susceptibility of campylobacter-pylori to antimicrobial agents. Eur J Clin Microbiol. 1989;8(10):888–889.
   Google Scholar
• Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81(4):521–528.
   PubMed Web of Science ®Google Scholar
• Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39(1):5–12.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Spiller RC, Barrett DA, et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter. 2003;8(4):294–299.
   PubMed Web of Science ®Google Scholar
• Schwartz H, Krause R, Sahba B, et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol. 1998;93(4):584–590.
   PubMed Web of Science ®Google Scholar
• Lindberg P, Keeling D, Fryklund J, et al. Review article: esomeprazole–enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther. 2003;17(4):481–488.
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–827.
   PubMed Web of Science ®Google Scholar
• Gatta L, Perna F, Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemoth. 2003;51(2):439–442.
   PubMed Web of Science ®Google Scholar
• Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31(1):9–28.
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27–36.
   PubMed Web of Science ®Google Scholar
• Ram MR, Teh X, Rajakumar T, et al. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. J Antimicrob Chemother. 2019;74(1):11–16.
   PubMed Web of Science ®Google Scholar
• Han R, Lu H, Jiang M-W, et al. Multicenter study of antibiotic resistance profile of H. pylori and distribution of CYP2C19 gene polymorphism in rural population of Chongqing, China. Gastroenterol Res Pract. 2016;2016:8547686.
   PubMed Web of Science ®Google Scholar
• Hu YM, Xu JM, Mei Q, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin. 2005;26(3):384–388.
   PubMed Web of Science ®Google Scholar
• Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors–focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(Suppl 6):11–19.
   PubMedGoogle Scholar
• Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15(12):1929–1937.
   PubMed Web of Science ®Google Scholar
• Lou HY, Chang CC, Sheu MT, et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65(1):55–64.
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65(5):552–561.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther. 2001;70(5):484–492.
   PubMed Web of Science ®Google Scholar
• Kang JM, Kim N, Lee DH, et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol. 2008;23(8):1287–1291.
   PubMed Web of Science ®Google Scholar
• Ormeci A, Emrence Z, Baran B, et al. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. Eur Rev Med Pharmacol Sci. 2016;20(5):879–885.
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027–1030.
   PubMed Web of Science ®Google Scholar
• Oh JH, Dong MS, Choi MG, et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol. 2009;24(2):294–298.
   PubMed Web of Science ®Google Scholar
• Hu JL, Yang J, Zhou YB, et al. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol. 2017;23(5):275–280.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004;76(4):290–301.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36(7):627–634.
   PubMed Web of Science ®Google Scholar
• Furuta T, Takashima M, Shirai N, et al. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther. 2000;67(6):684–689.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24(2):395–403.
   PubMed Web of Science ®Google Scholar
• Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28(4):448–451.
   PubMed Web of Science ®Google Scholar
• Graham DY, Javed SU, Keihanian S, et al. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010;45(8):816–820.
   PubMed Web of Science ®Google Scholar
• van der Wouden EJ, Thijs JC, van Zwet AA, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol. 1999;94(7):1751–1759.
   PubMed Web of Science ®Google Scholar
• Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000;14(6):745–750.
   PubMed Web of Science ®Google Scholar
• Gao CP, Zhou Z, Wang JZ, et al. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: a systematic review and meta-analysis. J Dig Dis. 2016;17(12):811–819.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang JX, Han SX, et al. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14396.
   Web of Science ®Google Scholar
• Argueta EA, Moss SF. Treatment of Helicobacter pylori. Curr Opin Gastroenterol. 2019;35(6):544–550.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the maastricht V/florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Long X, Chen Q, Yu L, et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23(3):e12485.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017;47(12):1027–1034.
   PubMed Web of Science ®Google Scholar
• Shinmura T, Adachi K, Yamaguchi Y, et al. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection. J Gastrointestin Liver Dis. 2019;28(4):389–395.
   PubMed Web of Science ®Google Scholar
• Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication. Intern Med. 2020;59(2):153–161.
   PubMed Web of Science ®Google Scholar
• Hwong-Ruey Leow A, Chang JV, Goh KL. Searching for an optimal therapy for H pylori eradication: high-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days. Helicobacter. 2020;e12723. DOI:10.1111/hel.12723
   PubMed Web of Science ®Google Scholar
• Luo L, Ji Y, Yu L, et al. 14-day high-dose amoxicillin- and metronidazole-containing triple therapy with or without bismuth as first-line helicobacter pylori treatment. Dig Dis Sci. 2020. DOI:10.1007/s10620-020-06115-7
   Web of Science ®Google Scholar
• Li B, Lan X, Wang L, et al. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: a meta-analysis. Microb Pathog. 2020;142:104075.
   PubMed Web of Science ®Google Scholar